Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers

Acquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have failed to produce durable treatment responses. Here, we developed multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Kris, Nussbaum, Daniel, Martz, Colin, Waters, Andrew, Barrera, Alejandro, Rutter, Justine, Cerda-Smith, Christian, Stewart, Amy, Wu, Chao, Cakir, Merve, Levandowski, Cecilia, Kantrowitz, David, McCall, Shannon, Pierobon, Mariaelena, Petricoin, Emanuel, Smith, J, Der, Channing, Taatjes, Dylan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635398/
https://www.ncbi.nlm.nih.gov/pubmed/37961649
http://dx.doi.org/10.21203/rs.3.rs-3511242/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635398/
https://www.ncbi.nlm.nih.gov/pubmed/37961649
http://dx.doi.org/10.21203/rs.3.rs-3511242/v1

Ejemplares similares